Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8
- Citation:
- Support Care Cancer vol 18 (3) 321-8
- Year:
- 2010
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Program:
- CCP
- Primary Committee:
- Symptom Inter
- Sec. Committees:
- Pharmas:
- Grants:
- CA 124477, U10 CA035267, N01 CA035431, CA-37404, K05 CA124477, CA-63844, CA-35195, U10 CA037404, N01 CA035119, U10 CA035195, CA-25224, N01 CA063844, CA 35431, U10 CA035272, U10 CA035431, U10 CA035119, CA-35272, U10 CA025224, CA-35267, U10 CA063844
- Corr. Author:
- Authors:
- Ann E. Kearns Donald W. Northfelt Amylou C. Dueck Pamela J. Atherton Shaker R. Dakhil Kendrith M. Rowland Jyotsna Fuloria Patrick J. Flynn Todor Dentchev Charles L. Loprinzi
- Networks:
- Study
- NCCTG-N01C8
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Prostate cancer, Androgen deprivation therapy, Osteoporosis, Risedronate, Estradiol